ATE322540T1 - Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender - Google Patents

Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender

Info

Publication number
ATE322540T1
ATE322540T1 AT95903544T AT95903544T ATE322540T1 AT E322540 T1 ATE322540 T1 AT E322540T1 AT 95903544 T AT95903544 T AT 95903544T AT 95903544 T AT95903544 T AT 95903544T AT E322540 T1 ATE322540 T1 AT E322540T1
Authority
AT
Austria
Prior art keywords
recipient
donor
tumor
hematopoietic cells
transfer
Prior art date
Application number
AT95903544T
Other languages
English (en)
Inventor
Larry W Kwak
Dan L Longo
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE322540T1 publication Critical patent/ATE322540T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95903544T 1993-11-17 1994-11-16 Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender ATE322540T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/153,464 US5861158A (en) 1993-11-17 1993-11-17 Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor

Publications (1)

Publication Number Publication Date
ATE322540T1 true ATE322540T1 (de) 2006-04-15

Family

ID=22547332

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95903544T ATE322540T1 (de) 1993-11-17 1994-11-16 Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender

Country Status (8)

Country Link
US (1) US5861158A (de)
EP (1) EP0729507B1 (de)
JP (1) JPH09509649A (de)
AT (1) ATE322540T1 (de)
AU (1) AU701858B2 (de)
CA (1) CA2176738C (de)
DE (1) DE69434691D1 (de)
WO (1) WO1995014080A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029769A1 (en) * 1996-02-16 1997-08-21 Biomira Usa Inc. Vaccine for b-cell malignancies
US6017537A (en) * 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
DK1151300T3 (da) * 1998-12-23 2010-07-12 Medsaic Pty Ltd Assay til påvisning af en bindingspartner
IL142802A (en) * 2000-04-27 2015-01-29 Enzo Therapeutics Inc Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma
AU2002335815A1 (en) * 2001-10-16 2003-04-28 Rxkinetix, Inc. High-concentration protein formulations and method of manufacture
US9725768B2 (en) 2012-08-31 2017-08-08 Biovest International, Inc. Methods for producing high-fidelity autologous idiotype vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192537A (en) * 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US5614610A (en) * 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
WO1988000970A2 (en) * 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5470730A (en) * 1990-09-28 1995-11-28 Immunex Method for producing TH -independent cytotoxic T lymphocytes
US5460964A (en) * 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5296353A (en) * 1992-04-06 1994-03-22 The United States Of America As Represented By The Department Of Health And Human Services Evaluation and treatment of patients with progessive immunosuppression
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
US5635156A (en) * 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5514364A (en) * 1993-09-13 1996-05-07 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation

Also Published As

Publication number Publication date
AU701858B2 (en) 1999-02-04
CA2176738A1 (en) 1995-05-26
EP0729507A1 (de) 1996-09-04
US5861158A (en) 1999-01-19
JPH09509649A (ja) 1997-09-30
DE69434691D1 (de) 2006-05-18
WO1995014080A1 (en) 1995-05-26
EP0729507B1 (de) 2006-04-05
AU1256495A (en) 1995-06-06
CA2176738C (en) 2002-11-12

Similar Documents

Publication Publication Date Title
DE69521794T2 (de) Zellen mit mehreren geänderten epitopen auf einem oberflächeantigen zur verwendung in transplantation
Nakahara et al. Bone and cartilage formation in diffusion chambers by subcultured cells derived from the periosteum
Oursler et al. Identification of osteoclast-specific monoclonal antibodies.
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
WO1998021334A3 (en) Antibody mg1 recognizing a small subset of human hematopoietic cells
PT86792A (pt) Monoclonal antibodies against melanoma-associated antigens hybrid cell lines producing these antibodies and use therefor
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
CA2189778A1 (en) Use of fas ligand to suppress lymphocyte-mediated immune responses
NO981374L (no) Dendrittcellestimulerende faktor
Vischer Mitogenic factors produced by lymphocyte activation: effect on T-and B-cells
Baumal et al. Synthesis, Assembly and Secretion of γ-Globulin by Mouse Myeloma Cells: V. Balanced and Unbalanced Synthesis of Heavy and Light Chains by IgG-Producing Tumors and Cell Lines
ATE322540T1 (de) Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender
DE69624937T2 (de) Verfahren zur verminderung der strahlentherapie oder der radiomimetischen chemotherapie bei der transplantation von hematopoietischen, pluripotenten zellen
HK1011924A1 (en) Monoclonal antibodies to antigens expressed by hematopoietic facilitaroy cells.
JPS6445398A (en) Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
EP0251106A2 (de) Fusionsmethode
EP0251107A2 (de) Fusionsprodukte
Izzo et al. Preferential localization and rate of loss of labeled alloantibody from rat tumors and skin transplants carrying the corresponding alloantigen
Lewis et al. Foetal-associated material: its expression in long-term cultured human skin
CA2369616A1 (en) Somatic transgene immunization and related methods
WO1988000836A3 (fr) Immunosuppresseur et son procede de fabrication
PT83368A (en) Process for propagating microorganisms in vivo by using cell lines which lack human class ii histocompatibility antigens
Müller-Ruchholtz Mhc allograft immunogenicity Its Role in Bone Marrow Transplantation and Its Constant Downregulation
Umezawa et al. Identity of brain-associated small cell lung cancer antigen and the CD56 (NKH-1/Leu-19) leukocyte differentiation antigen and the neural cell adhesion molecule

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties